185 studies on Ghrelin mimetic class curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This research provides a strong preclinical rationale for using acylated ghrelin as a potential adjunctive therapy to mitigate the kidney damage caused by doxorubicin chemotherapy. For individuals undergoing DOX treat…
This research clarifies a specific neuro-hormonal survival circuit that maintains blood glucose during severe energy deficit. For individuals undergoing aggressive dieting, fasting, or experiencing conditions mimickin…
This research highlights a specific mechanism by which ghrelin protects the gut lining, suggesting its potential as a therapeutic agent for inflammatory bowel diseases like ulcerative colitis. For individuals explorin…
This study highlights a potential therapeutic role for acylated ghrelin (AG) in mitigating the cardiovascular damage associated with hyperthyroidism. For individuals exploring peptide therapies, this suggests AG or `G…
This research reinforces the link between ghrelin, mood, and cognitive function, suggesting a specific biological pathway (`cAMP-CREB` -> `BDNF`) through which this occurs. For individuals exploring peptides, this hig…
This study's elucidation of the atomic-level molecular recognition of ghrelin by its receptor provides invaluable structural templates that are poised to revolutionize rational drug design. By understanding exactly ho…
This research uncovers a novel mechanism by which oral L-ornithine stimulates growth hormone (GH) secretion, specifically implicating ghrelin receptor-mediated pathways. Understanding this interaction could open new a…
This study introduces aza-Isotryptophan as a novel and versatile building block for peptide chemistry, significantly expanding the chemical space available for designing new peptide-based drugs. The ability of azaItr-…
**GHRP-2 may offer a clinically viable, lower-risk alternative to ITT** for diagnosing secondary adrenal insufficiency in patients with hypopituitarism — a group in whom insulin-induced hypoglycemia carries elevated d…
**Peptide secretagogues do not merely turn up GH output — they fundamentally reshape the kinetics of each burst**, a finding with direct implications for dosing strategy. Clinicians and researchers using combined **GH…
**Clinicians and peptide users co-administering testosterone with GHRP-2 should recognize that testosterone itself — not its aromatized or 5alpha-reduced metabolites — is the primary amplifier of GHRP-2-driven pulsati…
**Clinicians managing TBI or SAH survivors should consider routine GH axis screening**, as hypopituitarism and aGHD are far more prevalent in this population than traditionally assumed. The **GHRP-2 test's <9 ng/mL cu…
**Clinicians and biohackers using sermorelin or GHRP-2** should recognize that abdominal fat is the dominant suppressor of combined secretagogue synergy — not simply age or low testosterone. **Reducing AVF before or a…
**The dissociation between GHRP-2's motor-inhibitory and appetite-stimulating effects has direct implications for clinical use.** For practitioners or researchers considering GHRP-2 in protocols targeting appetite or …
**Clinicians and peptide users targeting GH optimization cannot rely on testosterone normalization alone** to restore somatotropic function — AVF and IGF-I levels are independent, dominant modulators. For practitioner…
**GHRP-2's secretagog efficacy is uniquely insensitive to the hormonal and metabolic factors that blunt GHRH-driven GH release**, including visceral adiposity and the IGF-1 / IGFBP axis. For clinicians and researchers…
**Clinicians and researchers testing GH-axis function must control for age, estrogen status, and visceral fat simultaneously** — failing to account for any single factor can produce spurious group differences in secre…
This research highlights a significant potential for GHRP-2 as a therapeutic agent to combat the debilitating muscle wasting associated with severe thermal injuries. By attenuating the expression of key muscle breakdo…
This compelling case report highlights the significant potential of the GHRP-2 test as a highly sensitive and specific diagnostic marker for Cushing's disease, particularly in cases involving ACTH-producing pituitary …
**The antioxidant and anti-inflammatory profile of GHRP-2 does not automatically translate into structural plaque regression** — a critical distinction for anyone considering this peptide as a cardiovascular adjunct. …
**Clinicians and peptide users designing GH-stimulation protocols in women must account for menopausal status and concurrent estrogen exposure, not just dosing of the secretagogue itself.** The finding that GHRP-2 out…
**GHRP-2 cannot substitute for, or add value as, an AVP secretion provocateur**, meaning it should not be used to assess posterior pituitary function in clinical workups for diabetes insipidus or SIADH. Clinicians eva…
**GHRP-2 testing may offer a safer, equally informative alternative to ITT** for evaluating adrenal reserve in patients with hypothalamic or pituitary disease, particularly those for whom insulin-induced hypoglycemia …
**Clinicians and users employing GHRP-2 in hormonal contexts must account for background androgen status**: higher DHT strongly attenuates stimulated cortisol pulsatility, meaning men on 5α-reductase inhibitors (e.g.,…
This research provides compelling evidence that GHRP-2 can directly stimulate ACTH release from the pituitary gland, even when the hypothalamus is impaired. This direct action on the pituitary could make GHRP-2 a valu…
This research highlights the significant potential of GH-Releasing Peptide-2 (GHRP-2) as a safe, rapid, and reliable diagnostic tool for Growth Hormone Deficiency (GHD) in children. Given that the traditional Insulin …
**GHRP-2's protective window — a single subcutaneous dose 30 minutes before injury — highlights a prophylactic or peri-operative protocol angle** relevant to high-risk surgical or septic patients who can be identified…
**Any consumer purchasing this supplement was unknowingly ingesting a WADA-prohibited peptide capable of stimulating the hGH/IGF-1 axis**, with no dosing guidance, safety oversight, or disclosure. For athletes, a posi…
**Finding GHRP-2 in commercially available nutritional supplements** means athletes and consumers may be unknowingly ingesting a non-approved peptide with systemic GH-releasing activity, creating both unintentional do…
**GHRP-2 is an active masking agent for rhGH doping** that can depress a positive isoform test result by more than half — anyone combining GHRP-2 with rhGH for performance enhancement should understand this interactio…
This review solidifies the role of the **GHRP-2 test** as a viable, safe, and convenient diagnostic tool for **adult growth hormone deficiency**, offering an alternative to the more cumbersome insulin tolerance test. …
This study demonstrates a critical nuance in GH secretagogue therapy: simply stimulating a transient pulse of endogenous GH may not be sufficient to drive meaningful clinical outcomes like growth in GHD patients. For …
This research provides a proof-of-concept for creating a longer-lasting version of GHRP-2. For peptide users or clinicians, this could translate to less frequent dosing schedules while maintaining stable levels of gro…